Arcturus Therapeutics Holdings Inc. (ARCT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 11:21AM EST. Market open.
| Previous Close | 23.44 |
| Open | 23.50 |
| Bid | 23.54 x 900 |
| Ask | 23.64 x 900 |
| Day's Range | 23.19 - 23.78 |
| 52 Week Range | 14.21 - 37.75 |
| Volume | |
| Avg. Volume | 406,058 |
| Market Cap | 630.654M |
| Beta (5Y Monthly) | 2.58 |
| PE Ratio (TTM) | 6.28 |
| EPS (TTM) | 3.76 |
| Earnings Date | Nov 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56.31 |
Business WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, December 04, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m.
ZacksThe Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog.
ZacksBiotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
Regulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week.
© 2023 Yahoo. All rights reserved.